-
EP3612181
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3612181
| EP3612181 - COMBINATION THERAPIES WITH EHMT2 INHIBITORS [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 13.02.2026 Database last updated on 20.03.2026 | |
| Former | Examination is in progress Status updated on 02.03.2023 | ||
| Former | Request for examination was made Status updated on 24.01.2020 | ||
| Former | The international publication has been made Status updated on 27.10.2018 | Most recent event Tooltip | 13.02.2026 | Application deemed to be withdrawn | published on 18.03.2026 [2026/12] | Applicant(s) | For all designated states Epizyme, Inc. 400 Technology Square, 4th Floor Cambridge, MA 02139 / US | [2020/39] |
| Former [2020/09] | For all designated states Epizyme Inc 400 Technology Square, 4th Floor Cambridge, MA 02139 / US | Inventor(s) | 01 /
CAMPBELL, John Emmerson 581 Mt. Auburn Street Unit 1 Cambridge, MA 02138 / US | 02 /
DUNCAN, Kenneth William 105 Briar Lane Westwood, MA 02090 / US | 03 /
RAIMONDI, Maria Alejandra 22 McBride Street Jamaica Plain, MA 02130 / US | 04 /
KLAUS, Christine 225 Winslow Road Waban, MA 02468 / US | 05 /
PENEBRE, Elayne 26 Evergreen Avenue Auburndale, MA 02466 / US | [2020/13] |
| Former [2020/09] | 01 /
CAMPBELL, John Emmerson 581 Mt. Auburn Street Unit 1 Cambridge Massachusetts 02138 / US | ||
| 02 /
DUNCAN, Kenneth William 132 Roosevelt Avenue Norwood Massachusetts 02062 / US | |||
| 03 /
RAIMONDI, Maria Alejandra 22 McBride Street Jamaica Plain Massachusetts 02130 / US | |||
| 04 /
KLAUS, Christine 225 Winslow Road Waban Massachusetts 02468 / US | |||
| 05 /
PENEBRE, Elayne 26 Evergreen Avenue Auburndale Massachusetts 02466 / US | Representative(s) | Russell, Tim, et al Venner Shipley LLP 200 Aldersgate London EC1A 4HD / GB | [2020/09] | Application number, filing date | 18788629.6 | 20.04.2018 | [2020/09] | WO2018US28609 | Priority number, date | US201762488679P | 21.04.2017 Original published format: US 201762488679 P | US201762574147P | 18.10.2017 Original published format: US 201762574147 P | [2020/09] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2018195450 | Date: | 25.10.2018 | Language: | EN | [2018/43] | Type: | A1 Application with search report | No.: | EP3612181 | Date: | 26.02.2020 | Language: | EN | The application published by WIPO in one of the EPO official languages on 25.10.2018 takes the place of the publication of the European patent application. | [2020/09] | Search report(s) | International search report - published on: | US | 25.10.2018 | (Supplementary) European search report - dispatched on: | EP | 03.12.2020 | Classification | IPC: | A61K31/44, A61K31/505, A61K31/506, A61K31/203, A61K31/4375, A61K31/47, A61K31/496, A61K31/517, A61K31/519, A61K31/706, A61P35/00, A61P35/02 | [2021/01] | CPC: |
A61K31/506 (EP,CN,US);
A61K31/505 (CN);
A61K31/203 (EP,US);
A61K31/404 (CN);
A61K31/415 (CN);
A61K31/4184 (CN);
A61K31/423 (CN);
A61K31/428 (CN);
A61K31/437 (CN);
A61K31/4375 (EP,CN,US);
A61K31/44 (EP,CN,US);
A61K31/444 (CN);
A61K31/47 (EP,CN);
A61K31/496 (EP,US);
A61K31/517 (EP,CN,US);
A61K31/519 (EP,CN,US);
A61K31/706 (EP,US);
A61K45/06 (CN);
| C-Set: |
A61K31/203, A61K2300/00 (EP);
A61K31/404, A61K2300/00 (CN);
A61K31/415, A61K2300/00 (CN);
A61K31/4184, A61K2300/00 (CN);
A61K31/423, A61K2300/00 (CN);
A61K31/428, A61K2300/00 (CN);
A61K31/4375, A61K2300/00 (CN,EP);
A61K31/437, A61K2300/00 (CN);
A61K31/444, A61K2300/00 (CN);
A61K31/44, A61K2300/00 (CN);
A61K31/47, A61K2300/00 (CN,EP);
A61K31/496, A61K2300/00 (EP);
A61K31/505, A61K2300/00 (CN);
A61K31/506, A61K2300/00 (EP,CN);
A61K31/517, A61K2300/00 (EP,CN);
A61K31/519, A61K2300/00 (CN,EP); |
| Former IPC [2020/09] | A61K31/44, A61K31/505, A61K31/506 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2020/09] | Title | German: | KOMBINATIONSTHERAPIEN MIT EHMT2-INHIBITOREN | [2020/09] | English: | COMBINATION THERAPIES WITH EHMT2 INHIBITORS | [2020/09] | French: | THÉRAPIES D'ASSOCIATION AVEC DES INHIBITEURS D'EHMT2 | [2020/09] | Entry into regional phase | 19.11.2019 | National basic fee paid | 19.11.2019 | Search fee paid | 19.11.2019 | Designation fee(s) paid | 19.11.2019 | Examination fee paid | Examination procedure | 19.11.2019 | Examination requested [2020/09] | 01.10.2021 | Amendment by applicant (claims and/or description) | 01.03.2023 | Despatch of a communication from the examining division (Time limit: M04) | 21.06.2023 | Reply to a communication from the examining division | 28.02.2024 | Invitation to indicate the basis for amendments (Time limit: M01) | 21.06.2024 | Reply to an invitation to indicate the basis for amendments | 01.11.2025 | Application deemed to be withdrawn, date of legal effect [2026/12] | 17.11.2025 | Despatch of communication that the application is deemed to be withdrawn, reason: renewal fee not paid in time [2026/12] | Request for further processing for: | The application is deemed to be withdrawn due to failure to reply to the examination report | 21.06.2024 | Request for further processing filed | 21.06.2024 | Full payment received (date of receipt of payment) Request granted | 26.06.2024 | Decision despatched | The application is deemed to be withdrawn due to failure to reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report/Supplementary European search report | 01.10.2021 | Request for further processing filed | 01.10.2021 | Full payment received (date of receipt of payment) Request granted | 14.10.2021 | Decision despatched | Fees paid | Renewal fee | 27.04.2020 | Renewal fee patent year 03 | 27.04.2021 | Renewal fee patent year 04 | 27.04.2022 | Renewal fee patent year 05 | 27.04.2023 | Renewal fee patent year 06 | 13.03.2024 | Renewal fee patent year 07 | Penalty fee | Additional fee for renewal fee | 30.04.2025 | 08 M06 Not yet paid |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [XD] WO2015200329 (GENENTECH INC et al.) | [X] US2015274660 (PLIUSHCHEV MARINA A et al.) | [X] EP3442947 (EPIZYME INC et al.) [X] 1-5,8,11-15 * abstract * * page 232, column l; example 16 * * page 20; table 1 * * examples 7,21-26 * * paragraph [0161] * * paragraph [0165] * | [XD] JING CUI ET AL: "EHMT2 inhibitor BIX-01294 induces apoptosis through PMAIP1-USP9X-MCL1 axis in human bladder cancer cells", CANCER CELL INTERNATIONAL, BIOMED CENTRAL, LONDON, GB, vol. 15, no. 1, 4 February 2015 (2015-02-04), pages 4, XP021211599, ISSN: 1475-2867, DOI: 10.1186/S12935-014-0149-X DOI: http://dx.doi.org/10.1186/s12935-014-0149-x | International search | [X] WO2012023285 (ONCOTHERAPY SCIENCE INC et al.) [X] 1-3 * ; para [0011], [0013], [0042] * | [A] WO2017061957 (AGENCY SCIENCE TECH & RES et al.) [A] 1-3 * ; entire document * | [A] CURRY ET AL.: "Dual EZH2 and EHMT2 histone methyltransferase inhibition increases biological efficacy in breast cancer cells", CLINICAL EPIGCNTICS, vol. 7, 21 August 2015 (2015-08-21), pages 1 - 12, XP055546034 [A] 1-3 * ; entire document * DOI: http://dx.doi.org/10.1186/s13148-015-0118-9 | Examination | WO2012023285 | A. RENNEVILLE ET AL: "EHMT1 and EHMT2 inhibition induces fetal hemoglobin expression", BLOOD, vol. 126, no. 16, 15 October 2015 (2015-10-15), US, pages 1930 - 1939, XP055456514, ISSN: 0006-4971, DOI: 10.1182/blood-2015-06-649087 DOI: http://dx.doi.org/10.1182/blood-2015-06-649087 |